GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Panbela Therapeutics Inc (OTCPK:PBLA) » Definitions » Shiller PE Ratio

Panbela Therapeutics (Panbela Therapeutics) Shiller PE Ratio : (As of Jun. 13, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Panbela Therapeutics Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Panbela Therapeutics Shiller PE Ratio Historical Data

The historical data trend for Panbela Therapeutics's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Panbela Therapeutics Shiller PE Ratio Chart

Panbela Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Panbela Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Panbela Therapeutics's Shiller PE Ratio

For the Biotechnology subindustry, Panbela Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Panbela Therapeutics's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Panbela Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Panbela Therapeutics's Shiller PE Ratio falls into.



Panbela Therapeutics Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Panbela Therapeutics's E10 for the quarter that ended in Mar. 2024 is calculated as:

For example, Panbela Therapeutics's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-2.28/131.7762*131.7762
=-2.280

Current CPI (Mar. 2024) = 131.7762.

Panbela Therapeutics Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201406 -9,553.500 100.560 -12,519.194
201409 -190,667.000 100.428 -250,183.442
201412 -162,667.000 99.070 -216,369.275
201503 -365,167.000 99.621 -483,033.410
201506 -202,500.000 100.684 -265,034.236
201509 -6,395.160 100.392 -8,394.435
201512 -5,870.970 99.792 -7,752.636
201603 -6,645.160 100.470 -8,715.740
201606 -7,409.090 101.688 -9,601.337
201609 -8,112.780 101.861 -10,495.394
201612 -16,701.500 101.863 -21,606.144
201703 -36,907.300 102.862 -47,281.740
201706 -9,302.630 103.349 -11,861.402
201709 -8,019.740 104.136 -10,148.411
201712 -13,506.200 104.011 -17,111.594
201803 -10,311.800 105.290 -12,905.844
201806 -11,833.300 106.317 -14,666.989
201809 -4,404.760 106.507 -5,449.822
201812 -3,507.110 105.998 -4,360.026
201903 -7,492.890 107.251 -9,206.340
201906 -9,542.020 108.070 -11,635.208
201909 -4,978.260 108.329 -6,055.754
201912 -3,528.990 108.420 -4,289.213
202003 -6,514.490 108.902 -7,882.855
202006 -1,425.170 108.767 -1,726.654
202009 -4,156.720 109.815 -4,988.000
202012 -2,189.050 109.897 -2,624.869
202103 -5,373.810 111.754 -6,336.576
202106 -5,204.760 114.631 -5,983.208
202109 -3,831.840 115.734 -4,362.970
202112 -6,317.860 117.630 -7,077.677
202203 -6,546.430 121.301 -7,111.761
202206 -25,583.800 125.017 -26,967.063
202209 -5,083.140 125.227 -5,349.003
202212 -3,408.000 125.222 -3,586.383
202303 -392.760 127.348 -406.418
202306 -159.000 128.729 -162.764
202309 -53.800 129.860 -54.594
202312 -13.487 129.419 -13.733
202403 -2.280 131.776 -2.280

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Panbela Therapeutics  (OTCPK:PBLA) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Panbela Therapeutics Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Panbela Therapeutics's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Panbela Therapeutics (Panbela Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
712 Vista Boulevard, Suite 305, Waconia, MN, USA, 55387
Panbela Therapeutics Inc is a clinical-stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs. The Company's pipeline assets are ivospemin (SBP-101), FlynpoviTM (eflornithine (CPP-1X) and sulindac), and eflornithine (CPP-1X), which provide a multi-targeted approach to reset dysregulated biology present in many types of diseases such as cancer and autoimmunity.
Executives
Jennifer K. Simpson director, officer: President and CEO C/O DELCATH SYSTEMS, INC., 810 SEVENTH AVENUE, SUITE 3505, NEW YORK NY 10019
Susan Horvath officer: V.P. of Finance & CFO 4645 ITHACA LANE, PLYMOUTH MN 55446
Jeffrey E. Jacob director 712 VISTA BLVD #305, WACONIA MN 55387
Daniel Donovan director 712 VISTA BLVD #305, WACONIA MN 55387
Paul W. Schaffer director 712 VISTA BLVD #305, WACONIA MN 55387
Arthur Fratamico director C/O FLEXION THERAPEUTICS, INC., 10 MALL ROAD, SUITE 301, BURLINGTON MA 01803
Ryan R. Gilbertson 2012 Irrevocable Trust 10 percent owner 1000 PARKER'S LAKE RD, WAYZATA MN 55391
Ryan Randall Gilbertson 10 percent owner 130 LAKE ST. WEST, WAYZATA MN 55391
Donald Robert Schemel director 712 VISTA BLVD #305, WACONIA MN 55387
Dalvir S Gill director 712 VISTA BLVD SUITE 305, WACONIA MN 55387
Scott Kellen officer: Chief Financial Officer 3405 ANNAPOLIS LANE, SUITE 200, MINNEAPOLIS MN 55447
Jeffrey S Mathiesen director 43334 SEVEN MILE RD., SUITE 1000, NORTHVILLE MI 48167
Paulson J Robert Jr director
Daniel E. Ryweck officer: Chief Financial Officer 712 VISTA BLVD #305, WACONIA MN 55387
Michael T. Cullen director 712 VISTA BLVD, #305, WACONIA MN 55387